Member Info for Saint68

Anyone reading anything by MF needs their head read. Bunch of chancers and they flip flop depending on their position. Avoid at all costs.

Ffs Aldebaran its board not bored.

Easiest binning for a while - bye doug.

Waltz - ex national security advisor

Another charter binned

Ffs Richy give it a rest. 2 day member and already knows it all.

I suggest anyone who mentions charts on an AIM share deserves to be binned immediately. AIM is sentiment driven so charting is completely pointless.

Don’t think Vlad will go down the CLN route again - once bitten, twice shy…

Big bird ? -thought it was almost rich - otherwise the i would not be a capital

JRDC - accelerated approval very much possible with Avacta due to their most advanced product being better than the current standard of care. Also there is no standard of care with their 2nd product so if trials go as expected I can see that being fast tracked too. A buyout later this year or H1 2026 is a real possibility.

Thanks and you too 👍

Hi JHFH - yes I have (for me) a large holding there and I’ve told you on several occasions that I’m a shareholder there and have been for a long time - prior to the cln debacle here. The dilution there is nothing compared to what we’ve had to endure here and only 400m shares in circulation and no consolidation. The next product to enter trials is truly groundbreaking and will hopefully be used in multiple cancer types including triple negative breast cancer - massive earning potential. The precision platform (already validated) will be worth far more than all our products combined - except if CBR does as Vlad says.

Avacta also have nearly a year of funding in the bank whereas here we’re surviving month to month. No matter how good the product candidates are, no money = no product.

The person who posted on the wrong board posts on both boards so I was merely pointing out that he needs to take more care to ensure he’s on the correct one before posting.

And just in case you want to compare graphs :

https://www.lse.co.uk/ShareChart.html?sharechart=HEMO&share=Hemogenyx

Another ridiculous comment JHFH - “ They are 20 times bigger than hemo and their pipeline sucks in comparison to Hemo” I’m afraid you’re very wide of the mark there. Hemo have dosed 1 patient, have virtually no cash and patient 2 has been delayed.

Avacta are 3 years into their trial with astonishing results to date and their pipeline is fantastic.

I suppose you think that the funding options that have plagued Hemo are a way better option ?

Wish all companies could have a business savvy board like Vlad and Peter (not).

The awful cln was arranged by our ex CEO and one of the reasons he was booted from his own company - something that Vlad needs to be aware of if things aren’t resolved here soon.

Wrong board. Think it should be on Avacta.

Aldebaran - “ chemo is most widely used drug in the world.” - no it’s not. Please stop posting your opinion as fact.

Glitch with lse - happens quite frequently.

Here’s one of the most recent : https://www.investorsinhealthcare.com/articles/category/analysis/one-of-the-largest-preclinical-adc-deals-taiho-pharmas-us1-14bn-acquisition-of-araris-biotech/

Not true. Many examples of pre-clinical deals available.

Phil “ Sell cbr or even the facility and rent it back..” - we don’t own the facility - it’s leased from Janus.